November 15th's MOUD Provider Collaborative meeting featured an introduction to the newest tool in the MOUD formulary: Brixadi, an FDA approved extended release formulation of injectable buprenorphine recently added to the Medicaid formulary. 

Dr. Jeanmarie Perrone, MD, Dr. Rachael Truchil, MD, MPH, and Dr. Kyle Kampman, MD shared their experiences with the drug for the treatment of OUD in various clinical settings. They covered a brief review of pharmacology, comparisons to Long Acting Buprenorphine (Sublocade), and highlighted practical insights through case discussion.